Effect of sex on survival after resection of oesophageal cancer: nationwide cohort study

Ji Zhang1*, Rino Bellocco1,2, Weimin Ye1,3, Jan Johansson4, Magnus Nilsson5,6 and Mats Lindblad5,6

1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
2Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy
3Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
4Department of Surgery, Skåne University Hospital, Lund University, Lund, Sweden
5Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden
6Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden

*Correspondence to: Ji Zhang, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE171 77, Stockholm, Sweden (e-mail: ji.zhang@ki.se)

The abstract of this manuscript was presented at the 17th International Society for Diseases of the Esophagus (ISDE) World Congress for Esophageal Diseases, September 27-30, 2021.

Abstract

Background: Accumulating evidence suggests a survival benefit after curative oesophageal cancer surgery in women compared with men. The aim of this study was to explore sex disparities in survival after surgery with curative intent in patients with oesophageal cancer.

Methods: This was a population-based cohort study, including all patients with oesophageal or gastric cancer who underwent surgery with a curative intent between 2006 and 2017 in Sweden. Female versus male mortality rate ratio (MRR) and excess mortality rate ratio (EMRR) were used as measures of survival. Two different parametric models were designed to account for potential confounders. Patients with gastric cancer were used as a comparison group as no differences in survival between sexes were expected among these patients.

Results: A total of 1301 patients underwent resection for oesophageal adenocarcinoma and 305 patients for oesophageal squamous cell carcinoma. Women had a lower EMRR (0.76, 95 per cent c.i. 0.58 to 1.01, P = 0.056; 0.52, 95 per cent c.i. 0.32 to 0.84, P = 0.007 respectively) in both histological subtypes. The effect was more profound in early clinical stages, in patients receiving neoadjuvant treatment, and without postoperative complications. No sex-related difference was observed in survival of patients with gastric cancer.

Conclusions: Women undergoing resection for oesophageal carcinoma have better survival compared with men.

Introduction

Oesophageal cancer is the ninth most common cancer diagnosis and the sixth most common cause of cancer-related death worldwide1. The incidence of oesophageal cancer is expected to rise and may cause an increased burden in the coming years due to an ageing population2,3. Although early diagnosis and better treatments have resulted in an improved prognosis, the 5-year survival rate remains low4,5.

Sex differences in the incidence of oesophageal cancer for both major histological subtypes, oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC), have been well described in many studies. Sex differences present substantial geographical variations that can be partly explained by different prevalence of risk factors, such as tobacco use and alcohol consumption6,7. Recent studies also suggest that sex may play a role in the prognosis after surgical treatment8–11. Surgical resection, together with chemotherapy, or chemoradiotherapy, is the treatment of choice for patients with non-metastatic locally advanced oesophageal cancer12,13. The 5-year survival rate after surgery is around 40 per cent for patients with OAC and OSCC in Sweden14. Patient characteristics such as age, smoking, co-morbidity, socioeconomic status, fitness, and performance status, as well as tumour-related factors such as tumour stage and biology are some of the factors that influence postoperative survival15–20.

The aim of this study was to explore potential sex differences in survival after curative surgery for OAC and OSCC. Patients with gastric cancer were included as a comparison group, as no sex differences in survival after curative intent resection were expected in these patients.

Methods

Database and study design

A review was performed to identify patients who underwent oesophagectomy for OAC or OSCC or gastrectomy for cancer between 2006 and 2017 from a prospectively developed...
nationwide disease-specific quality registry, the National Register for Oesophageal and Gastric Cancer (NREV). All patients were followed from the date of surgery until death, emigration, or end of follow-up (15 March 2018), whichever occurred first. Only patients who underwent surgery with curative intent, (surgery alone, neoadjuvant chemo- or chemoradiotherapy followed by surgery, or surgery with perioperative chemotherapy), were included. Data on diagnostic workup, treatment, and follow-up were entered into the NREV electronically by trained doctors and nurses. NREV has a coverage of 95.5 per cent, compared with the National Cancer Registry, and an accuracy of 91.1 per cent of all entries in the data, according to a validation study conducted in 2016. NREV was further linked to the Swedish registry of cause of death, Swedish National Inpatient Registry, and Total Population Registry to collect additional data and to perform censorship of follow-up. Detailed information regarding these registers is described elsewhere.

This study was approved by the Regional Ethical Review Board in Stockholm, Sweden (EPN Stockholm Dnr: 2016/1486-32 and 2013/596-31/3).

**Tumour classification**

NREV uses ICD-10 for the identification and categorization of tumour anatomical sites. Oesophageal cancer was defined as C15.0 to C16.0B or C16.0X, and gastric cancer was defined as C16.0C or C16.1 to C16.9. Patients without a definite histological identification were excluded from the analysis. Tumour stage was classified according to UICC TNM.

**Clinical variables**

Following a review of the literature, variables potentially affecting the prognosis of oesophageal cancer included age at time of surgery, Charlson co-morbidity index (0, 1, 2, and 3 or higher), ASA score, tumour stage, marital status (married, unmarried, divorced, and widowed), educational level (9 years or less, 10–12 years, and more than 12 years), neoadjuvant treatment (none, chemotherapy, and chemoradiotherapy), and hospital volume (defined as mean value of oesophagectomies or gastrectomies in each hospital per year, stratified by tertiles). Data on

### Table 1: Sex-specific main characteristics in groups of oesophageal adenocarcinoma and oesophageal squamous cell carcinoma

|                                | Oesophageal adenocarcinoma | Oesophageal squamous cell carcinoma |
|--------------------------------|-----------------------------|-----------------------------------|
|                                | Men (n = 1098)              | Women (n = 203)                   |
| **Age at operation (years)**   |                             |                                   |
| ≤9 years                       | 66.1 (9.0)                  | 65.6 (10.8)                       |
| 10–12 years                    | 503 (46.5)                  | 86 (43.2)                         |
| >12 years                      | 221 (20.5)                  | 53 (26.6)                         |
| Missing                        | 17                          | 4                                 |
| **Marital status**             |                             |                                   |
| Married                        | 659 (60.0)                  | 89 (43.8)                         |
| Unmarried                      | 171 (15.6)                  | 39 (19.2)                         |
| Divorced                       | 199 (18.1)                  | 35 (17.3)                         |
| Widowed                        | 69 (6.3)                    | 40 (19.7)                         |
| **Anaesthetist score**         |                             |                                   |
| 1                              | 389 (36.0)                  | 74 (37.2)                         |
| 2                              | 526 (48.7)                  | 93 (46.7)                         |
| 3                              | 156 (14.5)                  | 32 (16.1)                         |
| 4                              | 9 (0.8)                     | 0                                 |
| Missing                        | 18                          | 4                                 |
| **Clinical stage**             |                             |                                   |
| Stage 0                        | 121 (11.1)                  | 27 (13.3)                         |
| Stage I                        | 292 (26.7)                  | 70 (34.5)                         |
| Stage II                       | 279 (25.5)                  | 51 (25.1)                         |
| Stage III                      | 387 (35.2)                  | 50 (24.6)                         |
| Stage IV                       | 16 (1.5)                    | 5 (2.5)                           |
| Missing                        | 3                           | 0                                 |
| **Neoadjuvant treatment**      |                             |                                   |
| None                           | 350 (33.5)                  | 83 (43.0)                         |
| Chemotherapy                   | 266 (25.5)                  | 49 (25.4)                         |
| Chemoradiotherapy              | 429 (41.0)                  | 61 (31.6)                         |
| Missing                        | 53                          | 10                                |
| **Charlson co-morbidity index**|                             |                                   |
| 0                              | 513 (46.7)                  | 106 (52.2)                        |
| 1                              | 262 (23.9)                  | 46 (22.7)                         |
| 2                              | 156 (14.2)                  | 29 (14.3)                         |
| >3                             | 167 (15.2)                  | 22 (10.8)                         |
| **Hospital volume**            |                             |                                   |
| Low volume (first tertile)     | 298 (27.2)                  | 68 (33.5)                         |
| Middle volume (second tertile) | 373 (34.1)                  | 55 (27.1)                         |
| High volume (third tertile)    | 423 (38.7)                  | 80 (39.4)                         |
| Missing                        | 4                           | 0                                 |
| **Postoperative complications**|                             |                                   |
| No                             | 656 (59.7)                  | 124 (61.1)                        |
| Yes                            | 442 (40.3)                  | 79 (38.9)                         |

*Values are mean (s.d.).
Values in parentheses are percentages.
postoperative complications rate, defined as any complication occurring within 30 days after surgery, were also collected.

**Outcomes**

Outcomes of interest in the study included mortality rate and excess mortality rate at 1 year, 5 years, 10 years, and across the whole follow-up interval.

**Statistical methods**

Female versus male mortality (MRR) and excess mortality rate ratio (EMRR), absolute differences in mortality, and excess mortality rate were used to study survival. Excess mortality rate was defined as the difference between the observed mortality rate in the study cohort and the expected mortality rate of the Swedish population in the same interval retrieved from the Human Mortality Database of Sweden (http://www.mortality.org), matched by age, sex, and calendar year. Excess mortality rate was used as a surrogate measure of cancer-specific mortality as it does not require any classification of cause of death that in everyday practice might be inaccurate, especially within 1 month of surgery.

Flexible parametric models were applied to compute MRRs and EMRRs in each group with the stpm2 Stata procedure. With the sex coefficient set to be time dependent, the method allowed for a flexible estimation of baseline hazard, enabling the prediction of mortality rate as a function of follow-up time with a specific pattern of covariates. Two different models were designed. Model 1 included age at the time of surgery, whereas model 2 included age at the time of surgery, Charlson co-morbidity index, ASA score, tumour stage, marital status, education level, and hospital volume. Each model was evaluated at 1 year, 5 years, 10 years, and across the whole follow-up time, in each type of cancer. To identify potential confounders, analyses were also stratified by tumour stage, neoadjuvant treatment, and postoperative complications. Degrees of freedom were determined by the Akaike information criterion, Bayesian information criterion, and likelihood ratio test.

Sex-specific mortality rates and excess mortality rates were predicted based on model 2 with the standsurv Stata postestimation command of the stpm2 procedure. Individual calculation of mortality and excess mortality rates were made by setting covariates as observational values and sex was fixed to be male and then female in the model, separately, whatever the

---

Table 2: Female versus male mortality rate ratio and excess mortality rate ratio at different follow-up times in each group

| Oesophageal adenocarcinoma: MRR model | Death number/person-years | Model 1* MRR | P | Model 2† MRR | P |
|---------------------------------------|--------------------------|--------------|---|--------------|---|
|                                       | Men | Women |               |     |               |     |
| 1 year                                | 270/961 | 40/181 | 0.80 (0.57, 1.12) | 0.194 | 0.82 (0.57, 1.19) | 0.297 |
| 5 years                               | 324/1691 | 53/373 | 0.78 (0.61, 1.00) | 0.046 | 0.78 (0.60, 1.01) | 0.060 |
| 10 years                              | 40/570 | 6/113 | 0.77 (0.61, 0.98) | 0.032 | 0.77 (0.60, 1.00) | 0.047 |
| Overall                               | 634/3249 | 99/671 | 0.77 (0.61, 0.98) | 0.031 | 0.77 (0.60, 1.00) | 0.047 |

| Oesophageal adenocarcinoma: EMRR model | Death number/person-years | Model 1* EMRR | P | Model 2† EMRR | P |
|---------------------------------------|--------------------------|--------------|---|--------------|---|
|                                       | Men | Women |               |     |               |     |
| 1 year                                | 270/961 | 40/181 | 0.78 (0.54, 1.13) | 0.189 | 0.82 (0.55, 1.21) | 0.312 |
| 5 years                               | 324/1691 | 53/373 | 0.77 (0.59, 1.01) | 0.058 | 0.77 (0.58, 1.03) | 0.080 |
| 10 years                              | 40/570 | 6/113 | 0.75 (0.58, 0.98) | 0.032 | 0.76 (0.58, 1.01) | 0.057 |
| Overall                               | 634/3249 | 99/671 | 0.75 (0.58, 0.98) | 0.032 | 0.76 (0.58, 1.01) | 0.056 |

| Oesophageal squamous cell carcinoma: MRR model | Death number/person-years | Model 1* MRR | P | Model 2† MRR | P |
|-----------------------------------------------|--------------------------|--------------|---|--------------|---|
|                                              | Men | Women |               |     |               |     |
| 1 year                                       | 55/168 | 20/97 | 0.66 (0.39, 1.11) | 0.116 | 0.92 (0.47, 1.78) | 0.794 |
| 5 years                                      | 69/269 | 24/203 | 0.53 (0.36, 0.78) | 0.001 | 0.51 (0.32, 0.81) | 0.004 |
| 10 years                                     | 11/88 | 4/83 | 0.54 (0.37, 0.79) | 0.002 | 0.52 (0.33, 0.81) | 0.004 |
| Overall                                      | 135/530 | 48/387 | 0.54 (0.37, 0.79) | 0.002 | 0.51 (0.33, 0.81) | 0.004 |

| Oesophageal squamous cell carcinoma: EMRR model | Death number/person-years | Model 1* EMRR | P | Model 2† EMRR | P |
|-----------------------------------------------|--------------------------|--------------|---|--------------|---|
|                                              | Men | Women |               |     |               |     |
| 1 year                                       | 55/168 | 20/97 | 0.66 (0.38, 1.15) | 0.146 | 0.98 (0.49, 1.99) | 0.963 |
| 5 years                                      | 69/269 | 24/203 | 0.52 (0.34, 0.78) | 0.002 | 0.50 (0.30, 0.82) | 0.006 |
| 10 years                                     | 11/88 | 4/83 | 0.53 (0.35, 0.79) | 0.002 | 0.52 (0.32, 0.84) | 0.007 |
| Overall                                      | 135/530 | 48/387 | 0.53 (0.35, 0.79) | 0.002 | 0.52 (0.32, 0.84) | 0.007 |

Values in parentheses are 95 per cent confidence intervals.

*Adjusted for age.

†Adjusted for age, co-morbidity, ASA level, clinical stage, neoadjuvant treatment, marital status, education level, and hospital volume. MRR, male mortality rate ratio; EMRR, excess mortality rate ratio.
actual sex was. Individual estimates were then averaged over the whole population with sex set to male or female separately. Thereafter, absolute differences and ratios of mortality rates and excess mortality rates between men and women were calculated and plotted over follow-up time to describe time trends.

As a sensitivity analysis, the results of the flexible parametric models were compared with a Cox regression model. All the analyses were performed on an intention-to-treat basis. All analyses were carried out with Stata 15.0 (StataCorp, College Station, Texas, USA). A P value <0.05 was considered statistically significant.

**Results**

A total of 1301 patients with OAC, 1098 men (84.4 per cent) and 203 women (15.6 per cent); 305 patients with OSCC, 199 men (65.2 per cent) and 106 women (34.8 per cent); and 1597 patients with gastric cancer, 940 men (58.9 per cent) and 657 women (41.1 per cent) were included in the study. Patient characteristics according to sex and histological subtypes are reported in Table 1. Patient characteristics of gastric adenocarcinoma are shown in Table S1.

**Fig. 1** Sex-specific excess mortality rates per 1000 person-years with corresponding 95 per cent confidence intervals in each group, adjusting for age, co-morbidity, ASA level, clinical stage, neoadjuvant treatment, marital status, education level, and hospital volume

- a Oesophageal adenocarcinoma
- b Oesophageal squamous cell carcinoma

**Fig. 2** Female versus male excess mortality rate ratios with corresponding 95 per cent confidence intervals in each group, adjusting for age, co-morbidity, ASA level, clinical stage, neoadjuvant treatment, marital status, education level, and hospital volume

- a Oesophageal adenocarcinoma
- b Oesophageal squamous cell carcinoma

Female versus male MRRs and EMRRs at different time points after surgery according to models 1 and 2 are presented in Table 2. In patients with OAC, women had a risk reduction of mortality and excess mortality rate slightly greater than 20 per cent overall and at 10 years after surgery according to model 1 (overall and at 10 years in model 1, MRR 0.77 (0.61–0.98); EMRR 0.75 (0.58–0.98)). No statistically significant differences in female versus male MRRs or EMRRs were found at any other time point and/or according to model 2. In patients with OSCC, women had almost half the mortality and excess mortality.
rate compared with men overall, at 5 and 10 years after surgery according to both models (overall model 1, MRR 0.54 (0.37–0.79); EMRR 0.53 (0.35–0.79); overall model 2, MRR 0.51 (0.33–0.81); EMRR 0.52 (0.32–0.84)). Time trends for excess mortality rates in the OAC and OSCC groups, adjusting for potential covariates according to model 2, are shown in Fig. 1. Time trends for mortality rates, adjusting for potential covariates according to model 2, are shown in Fig. S1. Time trends for female versus male EMRRs in OAC and OSCC groups, adjusting for potential covariates according to model 2, are shown in Fig. 2. Time trends for female versus male MRRs, adjusting for potential covariates according to model 2, are shown in Fig S2.

In patients with gastric cancer, there was no difference in mortality and excess mortality rates between men and women at any time point after surgery according to both models (Table S2).

---

### Table 3 Female versus male mortality rate ratios, excess mortality rate ratios stratified by clinical stages in each group

| Oesophageal adenocarcinoma (total number/death number) | MRR Model 1* | MRR Model 2† | EMRR Model 1* | EMRR Model 2† |
|--------------------------------------------------------|--------------|--------------|---------------|---------------|
| **Stage 0–I**                                           |              |              |               |               |
| Men (n = 413/212)                                       | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (n = 97/40)                                       | 0.79 (0.55, 1.15) | 0.65 (0.43, 0.98) | 0.79 (0.52, 1.22) | 0.59 (0.36, 0.97) |
| **Stage II**                                            |              |              |               |               |
| Men (n = 279/160)                                       | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (51/27)                                           | 0.82 (0.51, 1.32) | 0.86 (0.52, 1.42) | 0.81 (0.48, 1.37) | 0.88 (0.52, 1.50) |
| **Stage III–IV**                                        |              |              |               |               |
| Men (n = 403/259)                                       | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (55/32)                                           | 0.83 (0.54, 1.28) | 0.79 (0.51, 1.22) | 0.82 (0.51, 1.31) | 0.80 (0.51, 1.26) |

| Oesophageal squamous cell carcinoma (total number/death number) | MRR Model 1* | MRR Model 2† | EMRR Model 1* | EMRR Model 2† |
|---------------------------------------------------------------|--------------|--------------|---------------|---------------|
| **Stage 0–I**                                                 |              |              |               |               |
| Men (n = 62/45)                                               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (42/16)                                                 | 0.37 (0.19, 0.75) | 0.28 (0.11, 0.68) | 0.34 (0.15, 0.68) | 0.29 (0.11, 0.75) |
| **Stage II**                                                  |              |              |               |               |
| Men (n = 50/33)                                               | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (38/16)                                                 | 0.59 (0.30, 1.15) | 0.65 (0.29, 1.46) | 0.59 (0.28, 1.23) | 0.66 (0.26, 1.64) |
| **Stage III–IV**                                              |              |              |               |               |
| Men (86/56)                                                   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (26/16)                                                 | 0.92 (0.48, 1.77) | 0.65 (0.27, 1.52) | 0.92 (0.47, 1.82) | 0.62 (0.25, 1.56) |

Values in parentheses are 95 per cent confidence intervals.

*Adjusted for age.
†Adjusted for age, co-morbidity, ASA level, neoadjuvant treatment, marital status, education level, and hospital volume. MRR, male mortality rate ratio; EMRR, excess mortality rate ratio.
shown in Fig. S4. Time trends for female versus male MRRs and EMRRs, adjusting for potential covariates according to model 2, are shown in Fig. S5. Absolute difference of mortality rates and excess mortality rates are shown in Fig S6.

Stratified analyses by tumour stage, neoadjuvant therapy, and postoperative complications in patients with oesophageal cancer are shown in Tables 3–5 respectively. A reduction in mortality and excess mortality rate was observed in women with oesophageal cancer in stage I, who underwent neoadjuvant therapy and did not develop postoperative complications, regardless of histological subtype. In patients with oesophageal cancer with a more advanced disease, who did not receive neoadjuvant therapy but developed postoperative complications, no differences in mortality and excess mortality rate were observed between sexes.

Stratified analyses by tumour stage, neoadjuvant therapy, and postoperative complications in patients with gastric cancer are shown in Tables S3–S5 respectively.

In the sensitivity analysis, hazard ratios in each group were calculated with a Cox regression model with time after surgery and age as the time scale; the results did not substantially differ from the main analyses, and results are shown in Tables S6 and S7.

Discussion

In women undergoing oesophageal cancer surgery a survival benefit was observed compared with men. The survival benefit was greater in patients with OSCC compared with patients with OAC and persisted after stratified analyses in patients with an early tumour stage, who underwent neoadjuvant therapy, and did not develop postoperative complications.

Data available in the literature are conflicting. Studies from Japan and Sweden showed a survival benefit in women compared with men mostly in patients with OSCC, while a study from the US found no sex difference in overall survival in

### Table 4 Female versus male mortality rate ratios, excess mortality rate ratios stratified by perioperative neoadjuvant treatment in each group

| Oesophageal adenocarcinoma (total number/death number) | MRR Model 1* | MRR Model 2† | EMRR Model 1* | EMRR Model 2† |
|-------------------------------------------------------|--------------|--------------|---------------|---------------|
| Without neoadjuvant treatment                         |              |              |               |               |
| Men (n = 350/226)                                      | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (n = 83/47)                                      | 0.97 (0.69, 1.38) | 0.99 (0.68, 1.43) | 1.01 (0.68, 1.49) | 1.05 (0.69, 1.59) |
| With neoadjuvant treatment                             |              |              |               |               |
| Men (n = 695/391)                                      | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (n = 110/50)                                     | 0.67 (0.47, 0.95) | 0.63 (0.43, 0.90) | 0.66 (0.45, 0.96) | 0.62 (0.42, 0.92) |

| Oesophageal squamous cell carcinoma (total number/death number) | MRR Model 1* | MRR Model 2† | EMRR Model 1* | EMRR Model 2† |
|-----------------------------------------------------------------|--------------|--------------|---------------|---------------|
| Without neoadjuvant treatment                                   |              |              |               |               |
| Men (68/58)                                                     | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (51/30)                                                   | 0.64 (0.38, 1.07) | 0.67 (0.36, 1.26) | 0.63 (0.36, 1.11) | 0.69 (0.35, 1.37) |
| With neoadjuvant treatment                                      |              |              |               |               |
| Men (126/75)                                                    | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (51/17)                                                   | 0.37 (0.19, 0.72) | 0.32 (0.14, 0.70) | 0.36 (0.18, 0.73) | 0.31 (0.13, 0.71) |

Values in parentheses are 95 per cent confidence intervals.
*Adjusted for age.
†Adjusted for age, co-morbidity, ASA level, clinical stage, marital status, education level, and hospital volume. MRR, male mortality rate ratio; EMRR, excess mortality rate ratio.

### Table 5 Female versus male mortality rate ratios, excess mortality rate ratios stratified by postoperative complications in each group

| Oesophageal adenocarcinoma (total number/death number) | MRR Model 1* | MRR Model 2† | EMRR Model 1* | EMRR Model 2† |
|-------------------------------------------------------|--------------|--------------|---------------|---------------|
| Without neoadjuvant treatment                         |              |              |               |               |
| Men (656/359)                                        | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (124/58)                                       | 0.69 (0.50, 0.96) | 0.66 (0.46, 0.94) | 0.66 (0.45, 0.99) | 0.64 (0.42, 0.96) |
| With neoadjuvant treatment                            |              |              |               |               |
| Men (442/275)                                        | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (79/41)                                        | 0.87 (0.61, 1.26) | 0.89 (0.61, 1.32) | 0.88 (0.60, 1.30) | 0.91 (0.60, 1.38) |
| Without neoadjuvant treatment                         |              |              |               |               |
| Men (101/62)                                         | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (56/20)                                        | 0.41 (0.22, 0.76) | 0.28 (0.14, 0.58) | 0.41 (0.21, 0.81) | 0.28 (0.13, 0.63) |
| With neoadjuvant treatment                            |              |              |               |               |
| Men (98/73)                                          | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Women (50/28)                                        | 0.61 (0.36, 1.03) | 0.50 (0.26, 0.96) | 0.61 (0.35, 1.05) | 0.49 (0.25, 0.98) |

Values in parentheses are 95 per cent confidence intervals.
*Adjusted for age.
†Adjusted for age, co-morbidity, ASA level, clinical stage, marital status, education level, and hospital volume. MRR, male mortality rate ratio; EMRR, excess mortality rate ratio.
patients with oesophageal cancer, but, after adjusting for a limited number of confounders, women had a slightly higher mortality risk in tumour stage II/III11.

A potential explanation for the sex difference in survival after oesophageal cancer surgery is that oestrogen might play a protective role in the development and survival of oesophageal cancer12,33, although the specific biological mechanism is unknown. Studies stratified by age did not show a better survival in younger women with high levels of sex hormones9, which does not support a protective effect of oestrogen. Other explanations for the difference between men and women could involve socioeconomic status, lifestyle, alcohol consumption, tobacco use, and obesity as key factors for the prognosis of oesophageal cancer7,34. Abdominal obesity, which is prevalent in men, is suggested to be an independent risk factor for OAC and partly explained the male dominance in the incidence of OAC35,36. However, the association between obesity and the postoperative survival of OAC is controversial and the mechanism remains largely unclear. Meta-analysis showed that obese patients tend to be associated with surgical complications such as anastomotic leak, yet have a better 5-year survival17,18. On the other hand, obesity may bring difficulties to the accurate cancer diagnosis, lack of ideal calculation of chemotherapy doses, and complex postsurgical complications, which may lead to poorer treatment outcomes19. Additionally, sex differences in survival after oesophageal cancer treatment may also be related to administration of neoadjuvant therapy. Sex-related differences in the pharmacokinetics and pharmacodynamics might affect the exposure, clearance, efficacy, toxicity, and adverse effects of chemotherapy, thus women might be overtreated and men undertreated20,21. Women that received neoadjuvant chemoradiotherapy have also shown a better response to treatment and a lower risk for tumour recurrence22. It has also been shown among patients with locoregional disease treated with oesophagectomy that women received neoadjuvant therapy less frequently, had more positive margins, and a worse overall survival than men11.

In the present study, high completeness, precision, and correctness in follow-up information were reached combining and cross-matching data from several nationwide comprehensive healthcare registers23,24. Some limitations, however, need to be mentioned. Despite being a population-based study, further subgroup analysis was not feasible given the low incidence of oesophageal cancer in women. To perform excess mortality analysis sex, age, and calendar year only were used as matching factors. Detailed information about other potential confounding factors, such as dietary factors, tobacco use, alcohol consumption, and BMI were not available. Data on postoperative complications lacked detail on severity, therefore, conclusions that can be drawn on this subgroup of patients are limited.

**Funding**

J.Z. was supported by a scholarship from China Scholarship Council. M.L. was supported by the Swedish Cancer Society.

**Disclosure** The authors declare no conflict of interest.

**Supplementary material**

Supplementary material is available at BJS Open online.

**Data availability**

Data cannot be shared publicly because of regulations in the Swedish Data Protection Act (2018:218; 2019; 219) and Ethical Review Act (2003:460). Data are available from the holder of the NREV register (J. Johansson; Jan.johansson@med.lu.se) for researchers who meet the criteria for access to confidential data.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68:394–424.

2. Malhotra GK, Yanala U, Ravigati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. *J Surg Oncol* 2017; 115:564–579.

3. He H, Chen N, Hou Y, Wang Z, Zhang Y, Zhang G et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. *Thorac Cancer* 2020; 11:1121–1128.

4. Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. *World J Gastrointest Oncol* 2014; 6:112–120.

5. Xie SH, Lagergren J. A global assessment of the male predominance in esophageal adenocarcinoma. *Onctarget* 2016; 7:38876–38883.

6. Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End results (SEER) Registry 1973–2008. *Dis Esophaus* 2014; 27:757–763.

7. Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. *Cancer Epidemiol* 2013; 37:579–584.

8. Wang QL, Xie SH, Wahlin K, Lagergren J. Global time trends in the incidence of esophageal squamous cell carcinoma. *Clin Epidemiol* 2018; 10:717–728.

9. Kauppila JH, Wahlin K, Lagergren P, Lagergren J. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma. *Int J Cancer* 2019; 144:1284–1291.

10. Monta M, Otsu H, Kawa H, Kasagi Y, Kimura Y, Saeki H et al. Gender differences in prognosis after esophagectomy for esophageal cancer. *Surg Today* 2014; 44:505–512.

11. Nobel TB, Livshitz J, Eljaly M, Janjigian YY, Bains MS, Adusumilli PS et al. Unique considerations for females undergoing esophagectomy. *Ann Surg* 2020; 272:113–117.

12. Al-Batran SE, Homann N, Pauligk C, Goetz TE, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; 393:1948–1957.

13. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; 366:2074–2084.

14. Kauppila JH, Mattsson F, Brusselaers N, Lagergren J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. *BMJ Open* 2018; 8:e021495.

15. Sauvanet A, Mariette C, Thomas P, Lozac’h P, Segol P, Tiret E et al. Mortality and morbidity after resection for
adeno-carcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 2005;201:253–262.

16. Yamashita K, Watanabe M, Mine S, Fukudome I, Okamura A, Yuda M et al. The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent. Surg Today 2018;48:632–639.

17. Fuchs HF, Harnsberger CR, Broderick RC, Chang DC, Sandler BJ, Jacobsen GR et al. Mortality after esophagectomy is heavily impacted by center volume: retrospective analysis of the Nationwide Inpatient Sample. Surg Endosc 2017;31:2491–2497.

18. Ra J, Paulson EC, Kucharzczuk J, Armstrong K, Wirtalla C, Rapaport-Kelz R et al. Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol 2008;15:1577–1584.

19. Wright CD, Kucharzczuk JC, O’Brien SM, Grab JD, Allen MS. Predictors of major morbidity and mortality after thoracic esophageal surgery: a Society of Thoracic Surgeons General Thoracic Surgery database risk adjustment model. J Thorac Cardiovasc Surg 2009;137:587–595.

20. Wijnhoven BPL, Tran KTC, Esterman A, Watson DI, Tilanus HW. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007;245:717–725.

21. Linder G, Lindblad M, Djerf P, Elbe P, Johansson J, Lundell L et al. Validation of data quality in the Swedish national register for oesophageal and gastric cancer. Br J Surg 2016;103:1326–1335.

22. Brooke HL, Talbæk M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H et al. The Swedish cause of death register. Eur J Epidemiol 2017;32:765–773.

23. Ludvigsson JF, Andersson E, Ekborn A, Feychting M, Kim JL, Reuterwall C et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:1–16.

24. Linder G, Sandin F, Johansson J, Lindblad M, Lundell L, Hedberg J. Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden. Cancer Epidemiol 2018;52:91–98.

25. Brierley JD, Gospodarowicz MK, Wittekind C (eds.). TNM Classification of Malignant Tumours. Hoboken, NJ: John Wiley & Sons, 2017.

26. Haynes SR, Lawler PG. An assessment of the consistency of ASA physical status classification allocation. Anaesthesia 1995;50:195–199.

27. Dickman FW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006;260:103–117.

28. Welch HG, Black WC. Are deaths within 1 month of cancer-directed surgery attributed to cancer? J Natl Cancer Inst 2002;94:1066–1070.

29. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Statist J 2009;9:265–290.

30. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175–2197.

31. Lambert P. Standardized survival curves and related measures from flexible survival parametric models. In: London Stata Conference, vol. 14. London: Stata Users Group, 2018.

32. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol 2012;30:2265–2272.

33. Xie SH, Lagergren J. The Male predominance in esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2016;14:338–347.

34. Castro C, Peleteiro B, Lunet N. Modifiable factors and esophageal cancer: a systematic review of published meta-analyses. J Gastrointest Oncol 2018;9:37–51.

35. Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol 2014;6:534–549.

36. Ryan AM, Duong M, Healy L, Ryan SA, Parekh N, Reynolds JV et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011;35:309–319.

37. Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenterol Surg 2018;2:13–21.

38. Mengardo V, Pucetti F, Mc Cormack O, Chaudry A, Allum WH. The impact of obesity on esophagectomy: a meta-analysis. Dis Esophagus 2018;31:dox149.

39. Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol 2013;10:519–533.

40. Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 2019;30:1914–1924.

41. Ozdemir BC, Csajka C, Dotto GP, Wagner AD. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. J Clin Oncol 2018;36:2680–2683.

42. Rowse PG, Jaroszewski DE, Thomas M, Harold K, Harmsen WS, Shen KR. Sex disparities after induction chemoradiotherapy and esophagectomy for esophageal cancer. Ann Thorac Surg 2017;104:1147–1152.

43. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist 2018;23:1319–1327.

44. Tustui F, Takeda FR, Kimura CMS, Sallum RAA, Ribeiro U Jr, Cecconello I. Esophageal carcinoma: is squamous cell carcinoma different disease compared to adenocarcinoma? A transversal study in a quaternary high-volume hospital in Brazil. Arq Gastroenterol 2016;53:44–48.